Stockbroking | Wealth Management | Corporate Advice

August 11, 2026

EMERGING COMPANY

SPECULATIVE BUY (no change)

Stock code:	BB1 AU
Price:	A$0.695
12-month target price:	A$1.76
Previous target price:	A$1.76
Up/downside to target price:	153.2%
Dividend yield:	0.0%
12-month TSR*:	153.2%
Market cap:	A$107m
Average daily turnover:	0.14m
Index inclusion:	N/A

** Total stock return – Up/downside to target price + 12-month forward dividend yield.*

Price performance

(%)	1M	3M	12M	3Y
Absolute	9.4	14.9	58.0	-
Rel ASX/S&P200	4.6	8.8	53.1	-

Source: IRESS

Financial summary

	Jun-26A	Jun-27F	Jun-28F	Jun-29F
Revenue (A$m)	0.8	1.2	2.0	17.0
EBITDA Norm (A$m)	-7.1	-7.5	-7.6	6.5
NPAT (A$m)	-7.2	-7.3	-7.5	2.3
EPS Norm (A$)	-0.052	-0.048	-0.049	0.015
EPS Growth Norm (%)	14.3%	-7.2%	1.9%	NA
P/E Norm (x)	NA	NA	NA	47.1
DPS (A$)	0.000	0.000	0.000	0.000
Dividend Yield (%)	0.0%	0.0%	0.0%	0.0%
Franking (%)	NA	NA	NA	NA
EV/EBITDA (x)	-11.1	-12.6	-13.4	16.1
Gearing (Net Debt/EBITDA)	2.53	1.54	0.57	-0.25

Source: Company data, Morgans estimates

Related research

BB1 (SPEC BUY - TP A$1.76) - 14 May 2026

BB1 - 03 Feb 2026

Scott Power

+61 7 3334 4884

scott.power@morgans.com.au

Iain Wilkie

Analyst(s) own shares in the following stocks mentioned in this report:

– Blinklab

Blinklab

Positive ADHD results - a major milestone

- BB1 has released positive top-line results in its European ADHD study, which gives the company confidence to undertake a pilot study ahead of a pivotal study in the US. This follows a similar path the company is pursuing with autism (ASD).
- Following the release of the FY26 result, together with a A$17m capital raise, BB1 is financially well placed as the key catalyst of top line results for ASD approach.
- We have made no changes to our A$1.76 valuation and SPECULATIVE BUY recommendation.

Event

- ADHD top-line results and FY26 report.

Analysis of ADHD

- BB1 reported positive results from its European ADHD study, marking the first major step toward expanding its smartphone-based diagnostic platform beyond autism. The study assessed digital neurobehavioural biomarkers collected through a smartphone app in children aged 6-17 years and achieved **82% sensitivity** and **83% specificity** versus clinical diagnoses, demonstrating strong accuracy in identifying ADHD. The findings were derived from a robust dataset of 208 participants, including 117 children with confirmed ADHD and 91 neurotypical controls.
- The results support development of BB1 Dx2, an AI-driven diagnostic model designed to detect ADHD alongside autism using objective behavioural measures such as blinking and facial reflex responses captured via smartphone. Management believes, and we agree, that ADHD represents a significantly larger commercial opportunity than paediatric ASD given its higher prevalence and the limitations of current diagnostic pathways, which rely heavily on subjective clinical assessment.
- Importantly, the study was completed through BB1's collaboration with European mental health provider Mental Care Group (MCG) at no cost to the company, highlighting a capital-efficient development approach while allowing BB1 to retain ownership of all study data and intellectual property.
- Looking ahead, BB1 plans to follow a development and regulatory pathway similar to its ASD product, Dx1. Next steps include a US pilot study, followed by a prospective FDA registrational study aimed at obtaining regulatory clearance for ADHD use. The company also sees future opportunities in adult ADHD diagnosis, monitoring symptom severity and treatment response, and providing objective biomarkers for ADHD drug development.

Forecast and valuation update

- BB1 posted its FY26 result noting a net loss of A$7.2m with the major expense being R&D costs at A$4.7m. BB1 finished the year with cash reserves of A$17.9m, which provides a runway well into CY27.
- We use a risk-weighted net present value (rNPV) method to value BB1 at A$1.76 per share (ASD at A$1.06 and ADHD at A$0.70), with potential upside to A$3.19 on an unrisked basis.

Investment view

- BB1's smartphone-based neuro diagnostic platform initially targets significant market opportunities in ASD and ADHD with the potential to address other neurological conditions. We have used an rNPV valuation method to value BB1 at A$1.76. We have set our target price at the same level. We rate BB1 a SPECULATIVE BUY.

Price catalysts

- Complete recruitment of the pivotal FDA 510(k) autism study - management expects top-line results in 4QCY26 with approval in 1QCY27.
- Early engagement with clinicians, Key Opinion Leaders (KOL), and potential commercial partners.

Risks

- Clinical risk: the clinical trials being undertaken may not achieve the primary endpoints. Regulatory risk: the diagnostic product may not achieve the required regulatory clearance.

Blinklab

SPECULATIVE BUY — as at August 11, 2026

Price (A$):	0.695	12-month target price (A$):	1.76
Market cap (A$m):	107	Up/downside to target price (%):	153.2
Free float (%):	45	Dividend yield (%):	0.0
Index inclusion:	N/A	12-month TSR (%):	153.2

BB1 was founded in 2021 by neuroscientists associated with Princeton University. The company's core offering is a smartphone-based neuroscience diagnostic platform, with its lead product focused on aiding the diagnosis of autism spectrum disorder (ASD) using neurometric testing analysed via machine learning.

R&D expenditure (A$m)



Source: Company reports

Operating cash outflow (A$m)



Source: Company reports

BB1's Autism timeline

BlinkLab Dx 1 – Autism Model	Calendar Year
Submit CE/MDR clearance	3Q 2026
Complete Pivotal Study (i.e. last patient tested)	4Q 2026
Submit Pivotal Study results to FDA	4Q 2026
Milestone: FDA responses on 510(k) clearance for Dx1	1Q 2027

Source: Company reports

Net cash balance (A$m)



Source: Company reports

Bull points

Capital Position: BB1 has been successful in raising capital to support its clinical programs.

Platform opportunities: BB1's platform has potential in diagnosing other conditions including Alzheimer's Disease.

Positive Clinical Data: Recent pilot trials have been encouraging and after discussions with the FDA a pivotal trial is due to start shortly with recruitment expected to be completed by the end of calendar 2026, according to management.

Bear points

Pre-revenue

BB1 is currently clinical stage and pre-revenue. There are no consensus expectations of first commercial revenues within three years.

Execution & Timing Risk: Key catalysts (notably data in ASD) is expected within 6 months and delays are possible.

Sector Headwinds: Biotech sector weakness, including risk-off investor sentiment and high short interest, may continue to weigh on the share price regardless of company progress.

ADHD study: key details and why it matters

The ADHD study represents BB1's first major effort to expand its diagnostic platform beyond autism into what management views as a substantially larger market opportunity. The study evaluated whether BB1's smartphone-based digital neurobehavioural biomarkers can distinguish children with ADHD from those without the condition.

Study design

- 375 children were initially recruited across multiple Mental Care Group (MCG) centres in the Netherlands and from the general community; and
- To create a cleaner dataset, children with other neurodevelopmental or psychiatric conditions, and those taking medication, were excluded.
- The final analysis included 208 children, comprising:
  - 117 children with clinically diagnosed ADHD (56%); and
  - 91 neurotypical controls (44%)

The cohort is notable because BB1 states it represents one of the largest case-control datasets reported for ADHD assessment tools.

How the technology works

Participants completed brief smartphone-based assessments that capture objective neurobehavioural biomarkers. Rather than relying on questionnaires alone, BB1's technology analyses subtle involuntary behaviours, including:

- Blink responses;
- Facial reflexes; and
- Other neurometric signals captured through smartphone cameras and sensors

These biomarkers are processed using machine learning algorithms to identify patterns associated with ADHD.

Results

The company's ADHD Dx2 machine-learning model achieved:

- 82% sensitivity: correctly identified 82% of children with ADHD; and
- 83% specificity: correctly classified 83% of children without ADHD.

Importantly, BB1 also found its objective biomarker measurements correlated with symptom assessments documented in clinical reports, supporting the clinical relevance of the underlying signals being measured.

Why these results could be important

ADHD diagnosis today is largely based on:

- Clinical interviews;
- Behavioural observations;
- Parent and teacher questionnaires; and
- Specialist judgement.

As a result, diagnosis can be subjective and time-consuming. BB1 argues its smartphone-based approach could provide a scalable, objective tool to support clinicians and reduce bottlenecks in diagnostic pathways.

Management noted that the observed accuracy may be approaching the practical limits achievable when benchmarked against subjective clinical diagnoses, given that even experienced clinicians can disagree on ADHD assessments.

Commercial significance

The results support development of BB1 Dx2, which would extend the existing autism platform (Dx1) into ADHD. ADHD has a much higher prevalence than autism, potentially expanding BB1's addressable market significantly. We value BB1 at A$1.76 on a risked basis (ASD at A$1.06 and ADHD at A$0.70) and A$3.19 on an unrisked basis.

Next steps

Investors should note this was an exploratory case-control study, not a regulatory study. BB1 plans to:

- Refine the ADHD Dx2 algorithm;
- Conduct a US pilot study with leading ADHD centres;
- Progress to a prospective FDA registrational study; and
- Pursue regulatory clearances in the US and potentially Europe.

Scan here for a full list of our branches.
1800 777 946
info@morgans.com.au

Scan here to explore the stocks under coverage of our award-winning in-house research team.

Scan here for research coverage policy, research independence statement & recommendation structure.

Scan here for a glossary of terms used in Morgans research.

Morgans Financial Limited ABN 49 010 669 726 AFSL 235410. Level 29, 123 Eagle Street, Brisbane, QLD 4000 Australia. A Participant of ASX Group.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("Morgans") do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so. Those acting upon such information without advice do so entirely at their own risk.

This report was prepared as private communication to clients of Morgans and is not intended for public circulation, publication or for use by any third party. The contents of this report may not be reproduced in whole or in part without the prior written consent of Morgans. While this report is based on information from sources which Morgans believes are reliable, its accuracy and completeness cannot be guaranteed. Any opinions expressed reflect Morgans judgement at this date and are subject to change. Morgans is under no obligation to provide revised assessments in the event of changed circumstances. This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever.

In Hong Kong, research is issued and distributed by Morgans (Hong Kong) Limited, which is licensed and regulated by the Securities and Futures Commission. Hong Kong recipients of this information that have any matters arising relating to dealing in securities or provision of advice on securities, or any other matter arising from this information, should contact Morgans (Hong Kong) Limited at hkresearch@morgans.com.au

Disclosure of interest: Morgans may from time to time hold an interest in any security referred to in this report and may, as principal or agent, sell such interests. Morgans may previously have acted as manager or co-manager of a public offering of any such securities. Morgans affiliates may provide or have provided banking services or corporate finance to the companies referred to in the report. The knowledge of affiliates concerning such services may not be reflected in this report. Morgans advises that it may earn brokerage, commissions, fees or other benefits and advantages, direct or indirect, in connection with the making of a recommendation or a dealing by a client in these securities. Some or all of Morgans Authorised Representatives may be remunerated wholly or partly by way of commission.

Regulatory disclosures: Analyst owns shares in the following mentioned company(ies): Blinklab

Morgans Corporate Limited is Joint lead Manager to the Placement of Shares for Blinklab in April 2026 and has received fees in this regard.